We predicted that during the course of this year, it would start to stabilise. We would see the beginnings recovery in that funding environ...

So, a return to growth in the second half on the revenue line and then operating leverage and improved margins in the second half of the ye...

Jonathan Hunt detailed the investment strategy of Syngene International, facing revenue growth challenges due to US biotech funding delays....

Syngene International, led by Jonathan Hunt, MD & CEO, remains committed to its long-term investment plans despite a guidance cut. The comp...

I think that restructuring and that evolution of becoming not only a bigger business, but one that is well balanced between both the manufa...

The first quarter revenue from operations rose 26% YoY to Rs. 832 crore. The earnings before interest, tax, depreciation and ammortisation ...

Syngene International also expects business growth from its pharma clients who are keen to make up for the time that they felt they lost du...

Syngene has raised the revenue guidance for FY23 from mid-teens to high teens due to significant depreciation of rupee against the dollar a...

“ Syngene has signed a 10-year strategic deal with Zoetis in animal health: It was a real piece of innovation from Zoetis and we are deligh...

In an interview to ET, Jonathan Hunt, CEO and MD of Syngene said the company has spare capacity and is also investing on expansion of micro...

“A young scientist joining a company like Syngene can travel the world scientifically without ever having to leave Bengaluru. It provides o...

"Given the second wave of the pandemic that we had in India, we have seen pretty strong sales on Remdesivir: the product that we manufactur...

“$100-120 million capex will be for a little bit of catch-up and the rest of it will be investment in the future growth of the company.”

Syngene, an arm of Biocon, is expanding its capital investment as it waits to complete a 40-acre, $100-million research facility in Mangalo...

Syngene offers integrated drug discovery and development services with capabilities in medicinal chemistry, biology and toxicology.

The company had posted a net profit of Rs 46.6 crore for the corresponding period of the previous fiscal, Syngene International said in a f...

Hunt will take charge after the retirement of current CEO Peter Bains in March, Syngene International said in a regulatory filing.